59 citations
,
January 2015 in “Nanoscale” The new micelle formulation delivers acne treatment more effectively and safely than current gels.
January 2025 in “Reactions Weekly” November 2024 in “Reactions Weekly” May 2023 in “Reactions Weekly”
38 citations
,
November 2016 in “Aaps Pharmscitech” Nanoparticles with more oleic acid improved the delivery and stability of the drug spironolactone.
January 2023 in “IntechOpen eBooks” The document concludes that specific methods for making diazine-based drugs can lead to high yields and are important for creating effective treatments for various diseases.
July 2025 in “The Journal of Dermatology” Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
The workshop promoted better medicine use and health practices through global collaboration.
36 citations
,
July 2017 in “Journal of controlled release” A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with fewer side effects.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
23 citations
,
October 2015 in “Plastic and reconstructive surgery/PSEF CD journals” Radiesse is a versatile facial injectable used for cosmetic improvements and long-term collagen production, with careful dosing needed to prevent complications.
4 citations
,
May 2024 in “Rapid Communications in Mass Spectrometry” Girard's reagent P improves detection of spironolactone and its metabolites.
2 citations
,
May 2013 in “The primary care companion for CNS disorders” A teenage girl's excessive hair growth was caused by a medication for mania, but improved after stopping the medication.
1 citations
,
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.
46 citations
,
May 2021 in “Stem Cell Research & Therapy” Strontium ranelate helps cartilage growth by blocking a specific cell pathway.
91 citations
,
August 2019 in “Frontiers in Microbiology” RpoS helps Borrelia burgdorferi survive in hosts and adapt to different environments.
Ritlecitinib is a new treatment for severe hair loss in people 12 and older.
13 citations
,
October 2023 in “Pharmaceutics” The new nasal gel for schizophrenia improved drug absorption and brain effects in rats.
5 citations
,
May 2017 in “Journal of dermatological science” The combined treatment effectively managed severe skin issues in Olmsted syndrome.
May 2024 in “Reactions weekly”
May 2026 in “Drug Delivery and Translational Research” Nanocarriers with spironolactone and 2-deoxy-D-ribose may improve hair loss treatment by targeting hair follicles directly.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
Anifrolumab improves quality of life and reduces steroid use in lupus patients.
16 citations
,
April 1985 in “Archives of dermatology” The summary does not report the effectiveness of Stanozolol in treating Pityriasis rubra pilaris.
8 citations
,
November 2002 in “The Canadian journal of psychiatry/Canadian journal of psychiatry” Increasing olanzapine caused hair loss in a woman, which stopped after changing medication.
5 citations
,
February 2025 in “Pediatric Dermatology” Ritlecitinib was generally well tolerated in children with alopecia areata.
10 citations
,
February 1976 in “The Journal of Dermatology” γ‐Oryzanol ointment increases sebaceous gland activity and sebum production.
March 2021 in “Research Square (Research Square)” Strontium ranelate helps cartilage growth by blocking a specific cell pathway.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.